We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Next-Generation Immunoassay Developed for Chagas Diseases

By LabMedica International staff writers
Posted on 26 Oct 2017
Print article
Image: Trypanosoma cruzi amastigotes in heart tissue from a patient with Chagas disease (Photo courtesy of the CDC).
Image: Trypanosoma cruzi amastigotes in heart tissue from a patient with Chagas disease (Photo courtesy of the CDC).
Chagas disease, caused by the protozoan Trypanosoma cruzi, is a major health and economic problem in Latin America for which no vaccine or appropriate drugs for large-scale public health interventions are yet available.

Accurate diagnosis is essential for the early identification and follows up of vector-borne cases and to prevent transmission of the disease by way of blood transfusions and organ transplantation. Diagnosis is routinely performed using serological methods, some of which require the laborious production of parasite lysates, parasite antigenic fractions or purified recombinant antigens.

Medical Parasitologists at the National University of General San Martín (Buenos Aires, Argentina) obtained human serum samples from T. cruzi-infected patients who were in the asymptomatic chronic stage of the disease without cardiac or gastrointestinal compromise (age range: 11 to 51 years old, median age: 20). Serum samples were collected from clotted blood obtained by venipuncture and analyzed for T. cruzi-specific antibodies with commercially available kits: enzyme-linked immunosorbent assay (ELISA) using total parasite homogenate and indirect hemagglutination (IHA).

The team performed a serological assessment of 27 selected epitopes and of their use in a novel multipeptide-based diagnostic method. A combination of seven of these peptides was finally evaluated in ELISA format against a panel of 199 sera samples (Chagas-positive and negative, including sera from patients with leishmaniasis). The multipeptide formulation displayed a high diagnostic performance, with a sensitivity of 96.3% and a specificity of 99.2%.

The authors concluded that their results provided a novel, robust multi-epitope formulation as a basis for the development of improved peptide-based serodiagnosis for chagas disease. In contrast with chimeric DNA constructs that encode multiepitope recombinant proteins, the fact that this diagnostic reagent is based on the combination of short peptides that can be synthesized separately and easily formulated in a mix-and-match approach, means that it can be improved successively over time with only a reasonable effort. The study was published on October 9, 2017, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
National University of General San Martín


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.